Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data
Amgen's Phase 3 study shows dazodalibep significantly improves systemic disease activity in adults with Sjögren's disease.
Share
Why It Matters
Amgen's new medicine worked well in testing for a serious disease. But the company must wait for another test before they can sell it.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.